COVID-19 Impact on Global Hormone Refractory Breast Cancer Market Size, Status and Forecast 2020-2026

August 2020 | 98 pages | ID: C94B4E20E095EN
QYResearch

Abstracts

This report focuses on the global Hormone Refractory Breast Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hormone Refractory Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
The key players covered in this study

• AstraZeneca
• AmpliMed Corporation
• Roche
• Bluefish Pharmaceuticals AB
• NeoCorp
• Sanofi Genzyme
• Neopharm
• Boehringer Ingelheim GmbH

Market segment by Type, the product can be split into

• Tumor Markers Therapy
• Gene Expression Therapy
• Gene Mutation Therapy

Market segment by Application, split into

• Scientific Research and Production
• Biological Science and Technology
• Medical Technology
• Medical Apparatus and Instruments

Market segment by Regions/Countries, this report covers

• North America
• Europe
• China
• Japan
• Southeast Asia
• India
• Central & South America

The study objectives of this report are:

• To analyze global Hormone Refractory Breast Cancer status, future forecast, growth opportunity, key market and key players.
• To present the Hormone Refractory Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Hormone Refractory Breast Cancer are as follows:

• History Year: 2015-2019
• Base Year: 2019
• Estimated Year: 2020
• Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Hormone Refractory Breast Cancer Revenue
1.4 Market Analysis by Type
  1.4.1 Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type: 2020 VS 2026
  1.4.2 Tumor Markers Therapy
  1.4.3 Gene Expression Therapy
  1.4.4 Gene Mutation Therapy
1.5 Market by Application
  1.5.1 Global Hormone Refractory Breast Cancer Market Share by Application: 2020 VS 2026
  1.5.2 Scientific Research and Production
  1.5.3 Biological Science and Technology
  1.5.4 Medical Technology
  1.5.5 Medical Apparatus and Instruments
1.6 Coronavirus Disease 2019 (Covid-19): Hormone Refractory Breast Cancer Industry Impact
  1.6.1 How the Covid-19 is Affecting the Hormone Refractory Breast Cancer Industry
    1.6.1.1 Hormone Refractory Breast Cancer Business Impact Assessment - Covid-19
    1.6.1.2 Supply Chain Challenges
    1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  1.6.2 Market Trends and Hormone Refractory Breast Cancer Potential Opportunities in the COVID-19 Landscape
  1.6.3 Measures / Proposal against Covid-19
    1.6.3.1 Government Measures to Combat Covid-19 Impact
    1.6.3.2 Proposal for Hormone Refractory Breast Cancer Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 GLOBAL GROWTH TRENDS BY REGIONS

2.1 Hormone Refractory Breast Cancer Market Perspective (2015-2026)
2.2 Hormone Refractory Breast Cancer Growth Trends by Regions
  2.2.1 Hormone Refractory Breast Cancer Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Hormone Refractory Breast Cancer Historic Market Share by Regions (2015-2020)
  2.2.3 Hormone Refractory Breast Cancer Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Top Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Porter’s Five Forces Analysis
  2.3.5 Hormone Refractory Breast Cancer Market Growth Strategy
  2.3.6 Primary Interviews with Key Hormone Refractory Breast Cancer Players (Opinion Leaders)

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Hormone Refractory Breast Cancer Players by Market Size
  3.1.1 Global Top Hormone Refractory Breast Cancer Players by Revenue (2015-2020)
  3.1.2 Global Hormone Refractory Breast Cancer Revenue Market Share by Players (2015-2020)
  3.1.3 Global Hormone Refractory Breast Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Hormone Refractory Breast Cancer Market Concentration Ratio
  3.2.1 Global Hormone Refractory Breast Cancer Market Concentration Ratio (CR5 and HHI)
  3.2.2 Global Top 10 and Top 5 Companies by Hormone Refractory Breast Cancer Revenue in 2019
3.3 Hormone Refractory Breast Cancer Key Players Head office and Area Served
3.4 Key Players Hormone Refractory Breast Cancer Product Solution and Service
3.5 Date of Enter into Hormone Refractory Breast Cancer Market
3.6 Mergers & Acquisitions, Expansion Plans

4 BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Hormone Refractory Breast Cancer Historic Market Size by Type (2015-2020)
4.2 Global Hormone Refractory Breast Cancer Forecasted Market Size by Type (2021-2026)

5 HORMONE REFRACTORY BREAST CANCER BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Hormone Refractory Breast Cancer Market Size by Application (2015-2020)
5.2 Global Hormone Refractory Breast Cancer Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Hormone Refractory Breast Cancer Market Size (2015-2020)
6.2 Hormone Refractory Breast Cancer Key Players in North America (2019-2020)
6.3 North America Hormone Refractory Breast Cancer Market Size by Type (2015-2020)
6.4 North America Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

7 EUROPE

7.1 Europe Hormone Refractory Breast Cancer Market Size (2015-2020)
7.2 Hormone Refractory Breast Cancer Key Players in Europe (2019-2020)
7.3 Europe Hormone Refractory Breast Cancer Market Size by Type (2015-2020)
7.4 Europe Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

8 CHINA

8.1 China Hormone Refractory Breast Cancer Market Size (2015-2020)
8.2 Hormone Refractory Breast Cancer Key Players in China (2019-2020)
8.3 China Hormone Refractory Breast Cancer Market Size by Type (2015-2020)
8.4 China Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

9 JAPAN

9.1 Japan Hormone Refractory Breast Cancer Market Size (2015-2020)
9.2 Hormone Refractory Breast Cancer Key Players in Japan (2019-2020)
9.3 Japan Hormone Refractory Breast Cancer Market Size by Type (2015-2020)
9.4 Japan Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

10 SOUTHEAST ASIA

10.1 Southeast Asia Hormone Refractory Breast Cancer Market Size (2015-2020)
10.2 Hormone Refractory Breast Cancer Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Hormone Refractory Breast Cancer Market Size by Type (2015-2020)
10.4 Southeast Asia Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

11 INDIA

11.1 India Hormone Refractory Breast Cancer Market Size (2015-2020)
11.2 Hormone Refractory Breast Cancer Key Players in India (2019-2020)
11.3 India Hormone Refractory Breast Cancer Market Size by Type (2015-2020)
11.4 India Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

12 CENTRAL & SOUTH AMERICA

12.1 Central & South America Hormone Refractory Breast Cancer Market Size (2015-2020)
12.2 Hormone Refractory Breast Cancer Key Players in Central & South America (2019-2020)
12.3 Central & South America Hormone Refractory Breast Cancer Market Size by Type (2015-2020)
12.4 Central & South America Hormone Refractory Breast Cancer Market Size by Application (2015-2020)

13 KEY PLAYERS PROFILES

13.1 AstraZeneca
  13.1.1 AstraZeneca Company Details
  13.1.2 AstraZeneca Business Overview and Its Total Revenue
  13.1.3 AstraZeneca Hormone Refractory Breast Cancer Introduction
  13.1.4 AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2015-2020))
  13.1.5 AstraZeneca Recent Development
13.2 AmpliMed Corporation
  13.2.1 AmpliMed Corporation Company Details
  13.2.2 AmpliMed Corporation Business Overview and Its Total Revenue
  13.2.3 AmpliMed Corporation Hormone Refractory Breast Cancer Introduction
  13.2.4 AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2015-2020)
  13.2.5 AmpliMed Corporation Recent Development
13.3 Roche
  13.3.1 Roche Company Details
  13.3.2 Roche Business Overview and Its Total Revenue
  13.3.3 Roche Hormone Refractory Breast Cancer Introduction
  13.3.4 Roche Revenue in Hormone Refractory Breast Cancer Business (2015-2020)
  13.3.5 Roche Recent Development
13.4 Bluefish Pharmaceuticals AB
  13.4.1 Bluefish Pharmaceuticals AB Company Details
  13.4.2 Bluefish Pharmaceuticals AB Business Overview and Its Total Revenue
  13.4.3 Bluefish Pharmaceuticals AB Hormone Refractory Breast Cancer Introduction
  13.4.4 Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2015-2020)
  13.4.5 Bluefish Pharmaceuticals AB Recent Development
13.5 NeoCorp
  13.5.1 NeoCorp Company Details
  13.5.2 NeoCorp Business Overview and Its Total Revenue
  13.5.3 NeoCorp Hormone Refractory Breast Cancer Introduction
  13.5.4 NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2015-2020)
  13.5.5 NeoCorp Recent Development
13.6 Sanofi Genzyme
  13.6.1 Sanofi Genzyme Company Details
  13.6.2 Sanofi Genzyme Business Overview and Its Total Revenue
  13.6.3 Sanofi Genzyme Hormone Refractory Breast Cancer Introduction
  13.6.4 Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2015-2020)
  13.6.5 Sanofi Genzyme Recent Development
13.7 Neopharm
  13.7.1 Neopharm Company Details
  13.7.2 Neopharm Business Overview and Its Total Revenue
  13.7.3 Neopharm Hormone Refractory Breast Cancer Introduction
  13.7.4 Neopharm Revenue in Hormone Refractory Breast Cancer Business (2015-2020)
  13.7.5 Neopharm Recent Development
13.8 Boehringer Ingelheim GmbH
  13.8.1 Boehringer Ingelheim GmbH Company Details
  13.8.2 Boehringer Ingelheim GmbH Business Overview and Its Total Revenue
  13.8.3 Boehringer Ingelheim GmbH Hormone Refractory Breast Cancer Introduction
  13.8.4 Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2015-2020)
  13.8.5 Boehringer Ingelheim GmbH Recent Development

14 ANALYST'S VIEWPOINTS/CONCLUSIONS

15 APPENDIX

15.1 Research Methodology
  15.1.1 Methodology/Research Approach
  15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Hormone Refractory Breast Cancer Key Market Segments
Table 2. Key Players Covered: Ranking by Hormone Refractory Breast Cancer Revenue
Table 3. Ranking of Global Top Hormone Refractory Breast Cancer Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Tumor Markers Therapy
Table 6. Key Players of Gene Expression Therapy
Table 7. Key Players of Gene Mutation Therapy
Table 8. COVID-19 Impact Global Market: (Four Hormone Refractory Breast Cancer Market Size Forecast Scenarios)
Table 9. Opportunities and Trends for Hormone Refractory Breast Cancer Players in the COVID-19 Landscape
Table 10. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 11. Key Regions/Countries Measures against Covid-19 Impact
Table 12. Proposal for Hormone Refractory Breast Cancer Players to Combat Covid-19 Impact
Table 13. Global Hormone Refractory Breast Cancer Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 14. Global Hormone Refractory Breast Cancer Market Size by Regions (US$ Million): 2020 VS 2026
Table 15. Global Hormone Refractory Breast Cancer Market Size by Regions (2015-2020) (US$ Million)
Table 16. Global Hormone Refractory Breast Cancer Market Share by Regions (2015-2020)
Table 17. Global Hormone Refractory Breast Cancer Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 18. Global Hormone Refractory Breast Cancer Market Share by Regions (2021-2026)
Table 19. Market Top Trends
Table 20. Key Drivers: Impact Analysis
Table 21. Key Challenges
Table 22. Hormone Refractory Breast Cancer Market Growth Strategy
Table 23. Main Points Interviewed from Key Hormone Refractory Breast Cancer Players
Table 24. Global Hormone Refractory Breast Cancer Revenue by Players (2015-2020) (Million US$)
Table 25. Global Hormone Refractory Breast Cancer Market Share by Players (2015-2020)
Table 26. Global Top Hormone Refractory Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Breast Cancer as of 2019)
Table 27. Global Hormone Refractory Breast Cancer by Players Market Concentration Ratio (CR5 and HHI)
Table 28. Key Players Headquarters and Area Served
Table 29. Key Players Hormone Refractory Breast Cancer Product Solution and Service
Table 30. Date of Enter into Hormone Refractory Breast Cancer Market
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 33. Global Hormone Refractory Breast Cancer Market Size Share by Type (2015-2020)
Table 34. Global Hormone Refractory Breast Cancer Revenue Market Share by Type (2021-2026)
Table 35. Global Hormone Refractory Breast Cancer Market Size Share by Application (2015-2020)
Table 36. Global Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 37. Global Hormone Refractory Breast Cancer Market Size Share by Application (2021-2026)
Table 38. North America Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$)
Table 39. North America Key Players Hormone Refractory Breast Cancer Market Share (2019-2020)
Table 40. North America Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 41. North America Hormone Refractory Breast Cancer Market Share by Type (2015-2020)
Table 42. North America Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 43. North America Hormone Refractory Breast Cancer Market Share by Application (2015-2020)
Table 44. Europe Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$)
Table 45. Europe Key Players Hormone Refractory Breast Cancer Market Share (2019-2020)
Table 46. Europe Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 47. Europe Hormone Refractory Breast Cancer Market Share by Type (2015-2020)
Table 48. Europe Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 49. Europe Hormone Refractory Breast Cancer Market Share by Application (2015-2020)
Table 50. China Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$)
Table 51. China Key Players Hormone Refractory Breast Cancer Market Share (2019-2020)
Table 52. China Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 53. China Hormone Refractory Breast Cancer Market Share by Type (2015-2020)
Table 54. China Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 55. China Hormone Refractory Breast Cancer Market Share by Application (2015-2020)
Table 56. Japan Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$)
Table 57. Japan Key Players Hormone Refractory Breast Cancer Market Share (2019-2020)
Table 58. Japan Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 59. Japan Hormone Refractory Breast Cancer Market Share by Type (2015-2020)
Table 60. Japan Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 61. Japan Hormone Refractory Breast Cancer Market Share by Application (2015-2020)
Table 62. Southeast Asia Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$)
Table 63. Southeast Asia Key Players Hormone Refractory Breast Cancer Market Share (2019-2020)
Table 64. Southeast Asia Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 65. Southeast Asia Hormone Refractory Breast Cancer Market Share by Type (2015-2020)
Table 66. Southeast Asia Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 67. Southeast Asia Hormone Refractory Breast Cancer Market Share by Application (2015-2020)
Table 68. India Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$)
Table 69. India Key Players Hormone Refractory Breast Cancer Market Share (2019-2020)
Table 70. India Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 71. India Hormone Refractory Breast Cancer Market Share by Type (2015-2020)
Table 72. India Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 73. India Hormone Refractory Breast Cancer Market Share by Application (2015-2020)
Table 74. Central & South America Key Players Hormone Refractory Breast Cancer Revenue (2019-2020) (Million US$)
Table 75. Central & South America Key Players Hormone Refractory Breast Cancer Market Share (2019-2020)
Table 76. Central & South America Hormone Refractory Breast Cancer Market Size by Type (2015-2020) (Million US$)
Table 77. Central & South America Hormone Refractory Breast Cancer Market Share by Type (2015-2020)
Table 78. Central & South America Hormone Refractory Breast Cancer Market Size by Application (2015-2020) (Million US$)
Table 79. Central & South America Hormone Refractory Breast Cancer Market Share by Application (2015-2020)
Table 80. AstraZeneca Company Details
Table 81. AstraZeneca Business Overview
Table 82. AstraZeneca Product
Table 83. AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$)
Table 84. AstraZeneca Recent Development
Table 85. AmpliMed Corporation Company Details
Table 86. AmpliMed Corporation Business Overview
Table 87. AmpliMed Corporation Product
Table 88. AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$)
Table 89. AmpliMed Corporation Recent Development
Table 90. Roche Company Details
Table 91. Roche Business Overview
Table 92. Roche Product
Table 93. Roche Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$)
Table 94. Roche Recent Development
Table 95. Bluefish Pharmaceuticals AB Company Details
Table 96. Bluefish Pharmaceuticals AB Business Overview
Table 97. Bluefish Pharmaceuticals AB Product
Table 98. Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$)
Table 99. Bluefish Pharmaceuticals AB Recent Development
Table 100. NeoCorp Company Details
Table 101. NeoCorp Business Overview
Table 102. NeoCorp Product
Table 103. NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$)
Table 104. NeoCorp Recent Development
Table 105. Sanofi Genzyme Company Details
Table 106. Sanofi Genzyme Business Overview
Table 107. Sanofi Genzyme Product
Table 108. Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$)
Table 109. Sanofi Genzyme Recent Development
Table 110. Neopharm Company Details
Table 111. Neopharm Business Overview
Table 112. Neopharm Product
Table 113. Neopharm Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$)
Table 114. Neopharm Recent Development
Table 115. Boehringer Ingelheim GmbH Business Overview
Table 116. Boehringer Ingelheim GmbH Product
Table 117. Boehringer Ingelheim GmbH Company Details
Table 118. Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2015-2020) (Million US$)
Table 119. Boehringer Ingelheim GmbH Recent Development
Table 120. Research Programs/Design for This Report
Table 121. Key Data Information from Secondary Sources
Table 122. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Hormone Refractory Breast Cancer Market Share by Type: 2020 VS 2026
Figure 2. Tumor Markers Therapy Features
Figure 3. Gene Expression Therapy Features
Figure 4. Gene Mutation Therapy Features
Figure 5. Global Hormone Refractory Breast Cancer Market Share by Application: 2020 VS 2026
Figure 6. Scientific Research and Production Case Studies
Figure 7. Biological Science and Technology Case Studies
Figure 8. Medical Technology Case Studies
Figure 9. Medical Apparatus and Instruments Case Studies
Figure 10. Hormone Refractory Breast Cancer Report Years Considered
Figure 11. Global Hormone Refractory Breast Cancer Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Hormone Refractory Breast Cancer Market Share by Regions: 2020 VS 2026
Figure 13. Global Hormone Refractory Breast Cancer Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Hormone Refractory Breast Cancer Market Share by Players in 2019
Figure 16. Global Top Hormone Refractory Breast Cancer Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hormone Refractory Breast Cancer as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Hormone Refractory Breast Cancer Revenue in 2019
Figure 18. North America Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Hormone Refractory Breast Cancer Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. AstraZeneca Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. AstraZeneca Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020)
Figure 27. AmpliMed Corporation Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. AmpliMed Corporation Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020)
Figure 29. Roche Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Roche Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020)
Figure 31. Bluefish Pharmaceuticals AB Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Bluefish Pharmaceuticals AB Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020)
Figure 33. NeoCorp Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. NeoCorp Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020)
Figure 35. Sanofi Genzyme Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Sanofi Genzyme Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020)
Figure 37. Neopharm Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Neopharm Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020)
Figure 39. Boehringer Ingelheim GmbH Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Boehringer Ingelheim GmbH Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2015-2020)
Figure 41. Bottom-up and Top-down Approaches for This Report
Figure 42. Data Triangulation
Figure 43. Key Executives Interviewed